Clinical and bacteriological efficacy of amikacin in the treatment of lower urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae

Journal of Infection and Chemotherapy

Volumn 20, Issue 12, 2014, Pages 762-767

  Ipekci, Tumay ^a   Seyman, Derya ^b   Berk, Hande ^b   Celik, Orcun ^c  

^a BASKENT UNIVERSITY   (Turkey)

^b Antalya Education and Research Hospital   (Turkey)

^c TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Amikacin; ESBL producing Escherichia coli or Klebsiella pneumonia; Lower urinary tract infection

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADULT; AGED; ARTICLE; ATAXIA; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; DYSURIA; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HEADACHE; HUMAN; INJECTION SITE PAIN; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; NEPHROTOXICITY; NYSTAGMUS; REINFECTION; RETROSPECTIVE STUDY; TINNITUS; URINARY TRACT INFECTION; URINARY URGENCY; URINE CULTURE; VERTIGO; VERY ELDERLY; ADOLESCENT; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84940102802     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2014.08.007     Document Type: Article

References (28)

1. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum betalactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection 2011;39:333-40.
2. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010;10:43-50.
3. Bours PH, Polak R, Hoepelman AI, Delgado E, Jarquin A, Matute AJ. Increasing resistance in community-acquired urinary tract infections in Latin America, five years after the implementation of national therapeutic guidelines. Int J Infect Dis 2010;14:770-4.
4. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community-and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis 2013;17:966-70.
5. Bouchillon SK, Badal RE, Hoban DJ, Hawser SP. Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. Clin Ther 2013;35:872-7.
6. Wayne PA. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI. CLSI document M100eS19. Clinical and Laboratory Standards Institute; 2009.
7. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
8. Singhal A, Sharma R, Jain M, Vyas L. Hospital and community isolates of uropathogens and their antibiotic sensitivity pattern from a tertiary care hospital in North West India. Ann Med Health Sci Res 2014;4:51-6.
9. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-902.
10. Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011;44:364-8.
11. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents 2012;40: 554-6.
12. Oteo J, Bautista V, Lara N, Cuevas O, Arroyo M, Fernandez S, et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010;65:2459-63.
13. Aypak C, Altunsoy A, Duzgun N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study. Ann Clin Microbiol Antimicrob 2009;8:27.
14. Garau J. Other antimicrobials of interest in the era of extended-spectrum betalactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 2008;14:198-202.
15. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 2007;6:4.
16. Tansarli GS, Athanasiou S, Falagas ME. Evaluation of antimicrobial susceptibility of Enterobacteriaceae causing urinary tract infections in Africa. Antimicrob Agents Chemother 2013;57:3628-39.
17. Lee DS, Choe HS, Lee SJ, Bae WJ, Cho HJ, Yoon BI, et al. Antimicrobial susceptibility pattern and epidemiology of female urinary tract infections in South Korea, 2010-2011. Antimicrob Agents Chemother 2013;57:5384-93.
18. Aykut AE, Karabiber N. Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics. Mikrobiyol Bul 2007;41:115-9.
19. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:103-20.
20. Jansaker F, Frimodt-Moller N, Sjogren I, Dahl KJ. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014;69: 769-72.
21. Titelman E, Iversen A, Kalin M, Giske CG. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 2012;18:189-92.
22. Senol S, Tasbakan M, Pullukcu H, Sipahi OR, Sipahi H, Yamazhan T, et al. Carbapenem versus fosfomycin tromethanol in the treatment of extendedspectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010;22:355-7.
23. Lee B, Kang SY, Kang HM, Yang NR, Kang HG, Ha IS, et al. Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extendedspectrum beta-lactamase-producing Enterobacteriaceae. Infect Chemother 2013;45:415-21.
24. Launay E, Bingen E, Cohen R. Therapeutics strategies for the management of urinary tract infection in children. Arch Pediatr 2012;19:109-16.
25. Fang GD, Brennen C, Wagener M, Swanson D, Hilf M, Zadecky L, et al. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother 1991;35:1849-55.
26. Gilbert D, Leggett JE. Aminoglycosdes. In: Mandell Gl, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone; 2010. p. 359-84.
27. Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006;57:780-3.
28. Hori J, Yamaguchi S, Osanai H, Kinebuchi T, Usami K, Takahashi N, et al. Clinical study of the urinary tract infections due to Escherichia coli harboring extended-spectrum beta lactamase. Hinyokika Kiyo 2007;53: 777-82.